Wound Management Technologies, Inc. Announces Increased Market Acceptance of CellerateRX

FORT WORTH, Texas, Feb. 26 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc. (OTC Bulletin Board:  WNDM) announced today that the recent increase in sales activities throughout the United States has resulted in 45 new clinicians evaluating their advanced wound care collagen product, CellerateRx® .  In the last two months, these evaluations have transpired into new customers in Arizona, New Mexico, South Carolina, North Dakota, New Jersey, Wyoming, Colorado, and New York.  

Cathy Bradshaw, President of Wound Care Innovations, LLC, a subsidiary of Wound Management Technologies, Inc, said, "We are excited about the number of new clinicians using CellerateRx®.   This has also resulted in an increase in the number of new distributors of our product around the country."

"The physicians that have contacted me have experienced outstanding clinical efficacy, particularly on diabetic and arterial ulcers when using CellerateRx®," states Dr. Larry Baratta, VP of Medical Affairs for Wound Care Innovations.  "They also commented on the reduction of pain as noted by their patients with arterial ulcers while achieving wound resolution."

CellerateRx® is a patented, one of a kind collagen product that is FDA approved for market for all acute and chronic wounds except 3rd degree burns.  It successfully addresses the multi-billion dollar wound care market.

For Wound Management Technologies Shareholder Information please call 954-357-0614 or go to http://www.woundmanagementtechnologies.com

About Wound Management Technologies, Inc.

Wound Management Technologies, Inc. (OTC Bulletin Board: WNDM - News), with its corporate headquarters in Fort Worth, Texas, and regional offices in Ft. Lauderdale, Florida is a rapidly growing provider of specialty medical products, advanced biotechnology solutions and technology applications to secure healthcare data delivery and messaging. The Company is following the lead of NASDAQ Biotech Stock INDEX leaders such as Celgene http://www.celgene.com, Geron http://www.geron.com, and Human Genome Sciences  http://www.hgsi.com by working to leverage its existing technology and infrastructure to develop opportunities within the International Biotechnology and Genetic Engineering fields. WNDM also has an interest in Cancer Treatment. For more information on the Company please visit http://www.woundmanagementtechnologies.com

Safe Harbor Statement:

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development and any other statements not constituting historical facts are "forward-looking statements," within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks, contingencies and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks, contingencies and uncertainties detailed in the Company's SEC filings, which could cause the company's actual operating results, performance or business plans or prospects to differ materially from those expressed in, or implied by these statements. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.

SOURCE Wound Management Technologies, Inc.